Loading page
Loading page
Loading substance route
Dosage information is tentative due to limited historical data on human use. LSZ's commercial availability only became widespread in 2013, resulting in a small body of documentation. Individual sensitivity may vary significantly; reports suggest LSZ may be slightly more potent than LSD, though this has not been definitively established.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
LSZ is not considered habit-forming and the desire to use it may actually decrease with repeated use. It is typically self-regulating in nature.
LSZ is not considered physiologically addictive. No physical dependence or withdrawal symptoms have been documented.
The exact toxic dose is unknown. Toxicity and long-term health effects have not been studied in any scientific context due to LSZ's status as a research chemical with very limited history of human usage.
Adverse psychological reactions including severe anxiety, paranoia, and psychosis are possible, particularly in individuals predisposed to mental illness. As a psychological amplifier, LSZ can intensify existing mental states and may produce paranoia or distressing experiences such as feelings of dying.
The development of LSZ traces back to efforts by David E. Nichols and colleagues at Purdue University to create conformationally restricted analogues of LSD for use as pharmacological research tools. The goal was to better understand how LSD orients itself when binding to the serotonin 5-HT2A…
Not scheduled under the UN Convention on Psychotropic Substances 1971
Not scheduled under the UN Single Convention on Narcotic Drugs 1961
Specifically named on the list of controlled substances as of August 25, 2015. Possession, distribution, and manufacture are prohibited.
Regulated under the Pharmaceutical Affairs Law (Pharmaceutical and Medical Device Act). Possession and sale are illegal without proper authorization.
Classified as a narcotic substance as of January 26, 2016, following its emergence on the designer drug market. Manufacturing, trade, and possession are prohibited.
Classified as a controlled drug under national drug legislation. Possession, production, supply, and importation are prohibited.
LSZ is not specifically scheduled at the federal level. However, as a structural analogue of LSD, it may be prosecuted under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. No cases for simple possession alone have been reported.
Controlled under the New Psychoactive Substances Act as of July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalty.
Controlled as a structural analogue of LSD under an amendment enacted on June 1, 2015. Although not officially scheduled by name, analogue provisions make it a controlled substance.
Specifically named and added to Verzeichnis E (Schedule E) of the controlled substances ordinance as of December 1, 2015.
Specifically named as a controlled substance under the Misuse of Drugs Act 1971 as of January 7, 2015. As a Class A substance, it carries the most severe penalties for possession, supply, and production.
12 sources cited